Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on July 5, 2021. The report discloses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Change in Certifying Accountants: On July 5, 2021, the Company engaged Frazier & Deeter, LLC as its independent registered public accounting firm for the fiscal year ending March 31, 2022.
- Previous Auditor: Marcum, LLP is currently completing the audit for the fiscal year ended March 31, 2021.
- Consultation History: During the fiscal years ended March 31, 2021 and 2020, the Company did not consult with Frazier & Deeter on accounting principles, audit opinions, or matters involving disagreements or reportable events.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies related to financial performance were disclosed in this document. The Company has provided Marcum, LLP with a copy of this disclosure and requested a letter addressed to the SEC regarding their agreement with the statements herein (filed as Exhibit 16.1).
Investor Verification Checklist
- Verify the content of the consent letter from Marcum, LLP (Exhibit 16.1) to ensure no disagreements exist regarding the change.
- Review the upcoming fiscal year 2022 audit report from Frazier & Deeter, LLC for any qualifications or emphasis of matter.
- Confirm the status of the fiscal year 2021 audit completion by Marcum, LLP.